• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lexaria Bioscience Corp.

News headline image
Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream
January 11, 2024
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
News headline image
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform
January 09, 2024
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
News headline image
Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space
November 01, 2023
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
News headline image
Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs
October 31, 2023
From Lexaria Bioscience Corp.
Via GlobeNewswire
Tickers LEXX
News headline image
Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events
July 27, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan
July 26, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Topics Supply Chain
Tickers LEXX LEXXW
News headline image
Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing
July 14, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria's Human Nicotine Study Nearing Start Date
July 13, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH
July 07, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Signs Manufacturing and License Agreements with BevNology
June 21, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Grants License to AnodGen Bioceuticals
June 08, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA
June 06, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market
June 03, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Grants License to Valcon Medical for the European Market
June 02, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Topics Cannabis
Tickers LEXX LEXXW
News headline image
Lexaria Announces 2022 Annual Meeting Results
June 01, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs
April 21, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Commences Multi-Week Human Clinical Hypertension Study
April 19, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results
April 14, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Provides Update on Human Nicotine Study NIC-H22-1
April 12, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Begins New Nicotine Formulation Creation and Evaluation Program
April 11, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Begins DehydraTECH-CBD Epilepsy Research Program
March 15, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Granted Important New Oral Nicotine Patent
March 08, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study
February 02, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Provides Annual Letter From the CEO
January 27, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2
January 18, 2022
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4
December 29, 2021
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
December 16, 2021
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
December 14, 2021
From Lexaria Bioscience Corp.
Via AccessWire
Tickers LEXX LEXXW
News headline image
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
December 08, 2021
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Tickers LEXX LEXXW
News headline image
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
November 10, 2021
From Lexaria Bioscience Corp.
Via AccessWire
Topics Death Intellectual Property
Tickers LEXX LEXXW
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap